{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:29:44Z","timestamp":1785288584102,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Dapagliflozin shows some potential in treating nonalcoholic fatty liver disease complicated with type 2 diabetes, and this meta-analysis aims to explore the efficacy of dapagliflozin vs placebo to treat nonalcoholic fatty liver disease complicated with type 2 diabetes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, EMbase, Web of science, EBSCO and Cochrane library databases have been searched through July 2024, and we included randomized controlled trials (RCTs) assessing the efficacy of dapagliflozin for nonalcoholic fatty liver disease complicated with type 2 diabetes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Five RCTs and 353 patients were included in the meta-analysis. Overall, compared with control intervention in patients with nonalcoholic fatty liver disease and type 2 diabetes, dapagliflozin treatment was able to significantly decrease ALT (standard mean difference [SMD]\u2005=\u2005\u22121.10; 95% confidence interval [CI]\u2005=\u2005\u22121.37 to \u22120.84; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001), AST (MD\u2005=\u2005\u22121.32; 95% CI\u2005=\u2005\u22121.76 to \u22120.88; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001) and HbA1c (SMD\u2005=\u2005\u22120.60; 95% CI\u2005=\u2005\u22121.02 to \u22120.17; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.006), but demonstrated no influence on fasting glucose (SMD\u2005=\u2005\u22120.55; 95% CI\u2005=\u2005\u22121.10 to 0; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.05), LDL-C (SMD\u2005=\u2005\u22120.19; 95% CI\u2005=\u2005\u22120.56 to 0.17; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.30) or triglyceride (SMD\u2005=\u2005\u22120.30; 95% CI\u2005=\u2005\u22121.47 to 0.88; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.62).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Dapagliflozin may benefit to treat patients with nonalcoholic fatty liver disease and type 2 diabetes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040836","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T14:06:24Z","timestamp":1736258784000},"page":"e40836","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9625-8222","authenticated-orcid":false,"given":"Hua","family":"Duan","sequence":"first","affiliation":[{"name":"Department of Tuberculosis, Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nan\u2019an District People\u2019s Hospital, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250909","doi-asserted-by":"crossref","first-page":"15489","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment.","volume":"23","author":"Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R2-20250909","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R3-20250909","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease.","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"R4-20250909","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"R5-20250909","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"R6-20250909","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/ijms17060928","article-title":"Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials.","volume":"17","author":"S\u00e1ez-Lara","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R7-20250909","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes.","volume":"65","author":"Hazlehurst","year":"2016","journal-title":"Metab Clin Exp"},{"key":"R8-20250909","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R9-20250909","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.beem.2016.06.006","article-title":"Non-alcoholic fatty liver disease and risk of type 2 diabetes.","volume":"30","author":"Lallukka","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R10-20250909","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R11-20250909","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise.","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"R12-20250909","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R13-20250909","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of \u2265 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis.","volume":"60","author":"Glass","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R14-20250909","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children.","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"R15-20250909","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.28484","article-title":"Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.","volume":"63","author":"Vilar-Gomez","year":"2016","journal-title":"Hepatology"},{"key":"R16-20250909","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients.","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"R17-20250909","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R18-20250909","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s13410-021-00980-2","article-title":"Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients.","volume":"42","author":"Hussain","year":"2021","journal-title":"Int J Diabetes Dev Countries"},{"key":"R19-20250909","doi-asserted-by":"crossref","first-page":"e13335","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.","volume":"73","author":"Aso","year":"2019","journal-title":"Int J Clin Pract"},{"key":"R20-20250909","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.","volume":"37","author":"Shi","year":"2023","journal-title":"J Diabetes Complications"},{"key":"R21-20250909","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R22-20250909","first-page":"1564","article-title":"Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials.","volume":"25","author":"He","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R23-20250909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R24-20250909","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses.","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"R25-20250909","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1945892419878315","article-title":"Efficacy of glutathione for patients with cystic fibrosis: a meta-analysis of randomized-controlled studies.","volume":"34","author":"Zhao","year":"2020","journal-title":"Am J Rhinol Allergy"},{"key":"R26-20250909","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R27-20250909","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"R28-20250909","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies.","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"R29-20250909","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.10.023","article-title":"PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.","volume":"66","author":"Mukhopadhyay","year":"2017","journal-title":"J Hepatol"},{"key":"R30-20250909","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3390\/antiox9111040","article-title":"Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 inflammasome-mediated hepatic inflammation in vivo and in vitro.","volume":"9","author":"Hwangbo","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"R31-20250909","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1111\/jcmm.14293","article-title":"Aucubin inhibited lipid accumulation and oxidative stress via Nrf2\/HO-1 and AMPK signalling pathways.","volume":"23","author":"Shen","year":"2019","journal-title":"J Cell Mol Med"},{"key":"R32-20250909","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.","volume":"85","author":"Garvey","year":"2018","journal-title":"Metab Clin Exp"},{"key":"R33-20250909","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.07.009","article-title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: Ex quo et quo vadimus?","volume":"98","author":"Katsiki","year":"2019","journal-title":"Metab Clin Exp"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:01:58Z","timestamp":1757440918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040836","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]}}}